 Nes Ziona, Israel, Aug. 09, 2021 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. Nasdaq: ENLV, the Company, a clinical-stage macrophage reprogramming immunotherapy company, today announced that financial results for the second quarter ended June 30, 2021 were filed with the SEC on August 6, 2021 and provided a business update. 